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A peptide derived from the N-terminal region of porcine prosomatostatin, proSS,_,,, has been purified to 
homogeneity from extracts of porcine upper intestine. Amino acid analysis revealed that the peptide consists 
of 32 residues. The complete primary structure was determined as: 
APSDPRLRQFLQKSLAAAAGKQELAKYFLAEL 
This sequence obviously comprises residues l-32 of porcine prosomatostatin since it is identical to the cor- 
responding sequence in human preprosomatostatin. The postulated cleavage site in porcine prosomatostatin 
is a Leu-Leu bond between residues 32 and 33, thus confirming previous studies of the processing of the 
somatostatin precursor in the rat and transgenic mouse. 
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1. INTRODUCTION 
The structure of preprosomatostatin (preproSS), 
the precursor of somatostatin-14 (SS-14) and 
somatostatin-28 (SS-28), has been deduced from 
nucleotide sequences of anglerfish [ 1,2], catfish 
[3-61, rat [7-91 and human [lo] cDNAs as well as 
from a human [l l] and rat [12] genomic library. 
The N-terminal part of prosomatostatin is highly 
conserved, so that only 2 residues are different be- 
tween the rat and human precursor. Very little, 
however, is known about the posttranslational 
processing of this region of prosomatostatin 
(proSS). SS-14, SS-28 and its N-terminal fragment, 
SS-281_ 12, have been isolated and characterized 
from mammalian tissues [ 13-181. It has been 
postulated that several other peptides may derive 
from the prosomatostatin sequence [19,201. 
While characterizing side-fractions obtained 
during the isolation procedure for vasoactive in- 
testinal peptide (VIP) from porcine gut extracts 
[21], we identified a pzptide with the N-terminal 
sequence of prosomatostatin. We report here the 
isolation, characterization and complete primary 
structure of this peptide derived from porcine pro- 
somatostatin, which we have designated 
‘proSS1_32’. 
2. MATERIALS AND METHODS 
2.1. Isolation of the peptide 
As starting material a highly purified peptide 
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fraction from an upper porcine gut extract, the 
‘post-secretin’ fraction, from which VIP has been 
isolated [21,22], was used. This material was 
chromatographed on a CM-cellulose column in 
20 mM Na-phosphate, pH 6.4, using a salt gra- 
dient (O-O.3 M NaCl) for elution (see legend to 
fig.1). Fractions I-VIII were further purified by 
high-performance liquid chromatography (HPLC) 
on a reversed-phase C-18 wide-pore column 
(Vydac RP 201 TPB) using a Waters HPLC 
system. Unidentified peaks were characterized 
after rechromatography by HPLC retention time 
and UV absorbance at 214 and 280 nm, compared 
to mixtures of known gastrointestinal peptides, 
used as reference. Structural information was 
gained by amino acid and N-terminal sequence 
analysis. 
Somatostatin-like immunoreactivity was mea- 
sured by radioimmunoassay using an antiserum 
directed towards the central residues of SS-14 that 
cross-reacts fully with SS-28 [23]. 
2.2. Structural analysis 
Amino acid composition was determined with a 
Durrum D-500 automatic amino acid analyzer 
after hydrolysis with 5.7 N HCl containing 0.5% 
phenol in evacuated tubes at 110°C for 24 or 72 h. 
For sequence determination the peptide was 
digested at 37°C with TPCK-trypsin in 0.1 M 
NH4HCO3, pH 8.2, for 4 h or with Staphylococ- 
cus aureus V8 protease in the same buffer, but at 
pH 7.8, for 48 h. The cleavage products were 
separated by HPLC. The primary structure was 
determined by manual DABITC-Edman degrada- 
tion (dimethylaminoazobenzene isothiocyanate 
method) [24], liquid-phase sequencing on a 
Beckman model 890 [25] or gas-phase sequencing 
on an Applied Biosystems model 470A [26]. The 
phenylhydantoin derivatives were identified by 
HPLC [27]. 
3. RESULTS 
3.1. Isolation of the peptide 
The initial cation-exchange chromatography of 
the starting material (‘post-secretin’ fraction) on 
CM-cellulose in 20 mM Na-phosphate, pH 6.4, is 
shown in fig. 1. Peptides were eluted by an NaCl 
gradient (O-O.3 M). Fractions I-VIII were further 
separated by reversed-phase HPLC on a Vydac 
142 
C-18 column in a trifluoroacetic acid 
(TFA)/acetonitrile solvent system as described in 
the legend to fig.2, which shows the HPLC absor- 
bance profile of fraction II. 
Retention time analysis, UV absorbance ratio at 
214 and 280 nm (not shown) and screening N- 
terminal sequence determination of the first 6 
residues by manual DABITC-Edman degradation 
revealed in this fraction the presence of several 
peptides with structural and chromatographic 
properties clearly different from those of previous- 
Fig. 1. Cation-exchange chromatography of the starting 
material (post-secretin fraction) on CM-cellulose in 
20 mM Na-phosphate, pH 6.4, using an NaCl gradient 
(O-O.3 M) for elution. Fractions I-VIII were further 
characterized by HPLC. 
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Fig.2. HPLC elution profile of fraction II from the CM- 
cellulose chromatography (fig. 1). 0.8 mg were applied to 
a Vydac RP 201 TPB reversed-phase wide-pore C-18 
column (IO/m, 300 A, 0.46 x 25 cm) and eluted at 
40°C with a linear gradient from 40 to 50% solvent B in 
65 min. Flow rate, 1.5 ml/min; solvent A, 0.1% TFA; 
solvent B, 0.12% TFA in 70% acetonitrile. Peaks were 
characterized by retention time analysis, UV absorbance 
at 214 and 280 nm (not shown) and N-terminal sequence 
determination. The peak marked P contained peptide 
proSSi_jz. 
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Fig.3. HPLC rechromatography of peak P from fig.2 
using a different linear gradient; other conditions were 
as described in fig.2. Peptide pros&-32 eluted in 
essentially pure form. 
ly isolated gastrointestinal peptides used as 
reference. The peak marked ‘P’ contained a pep- 
tide with the N-terminal sequence APSDPR which 
is identical with the N-terminus of pro- 
somatostatin. HPLC rechromatography of this 
peak in the TFA/acetonitrile system under the con- 
ditions detailed in the legend to fig.3 revealed the 
peptide in essentially pure form. It did not react 
with an antiserum directed against the SS-14 se- 
quence, thus indicating that the peptide was not 
identical with the complete prosomatostatin 
precursor, proSSr-92. 
3.2. Structural analysis 
Table 1 shows the amino acid analysis of the 
peptide. It comprises 32 residues. Tryptic cleavage 
resulted in 6 fragments (tl-t6) which were 
separated by HPLC as shown in fig.4, using the 
same chromatographic conditions as described in 
the legend to fig.2. By cleavage with S. aureus V8 
protease, 2 fragments were generated and complete 
separation was also achieved by HPLC (not 
shown). Table 1 shows the amino acid composi- 
tions of the enzymatic fragments. The intact pep- 
tide which we named proSSr-32 and fragment 
SV8-1 comprising 23 residues were degraded se- 
quentially up to position 20 by the manual 
DABITC-Edman method and by liquid-phase se- 
quencing. The primary structure of peptide t6 was 
established by gas-phase sequencing, all other en- 
zymatic fragments were completely sequenced 
manually. Fig.5 shows the amino acid sequence of 
proSSr-32. 
Table 1 
Amino acid compositions of proSSr_32 and its peptide fragments generated by cleavage with trypsin and S. aureus V8 
protease 
vroSSr-32 t1 t6 SV8-1 SV8-2 
Asp 1.1 (1) 1.1 (1) 1.1 (1) 
Ser 2.2 (2) 1.0 (1) 1.0 (1) 2.0 (2) 
Glu 5.6 (5) 2.2 (2) 2.0 (2) 1.3 (1) 4.3 (4) 1.0 (1) 
Pro 2.2 (2) 2.0 (2) 1.9 (2) 
Gly 1.2 (1) 1.1 (1) 1.4 (1) 
Ala 6.8 (7) 1.0 (1) 3.6 (4) 1.0 (1) 1.2 (1) 4.6 (5) 2.0 (2) 
Leu 6.6 (6) 1.0 (1) 1.0 (1) 1.2 (1) 1.0 (1) 2.5 (2) 2.9 (3) 2.6 (3)= 
Tyr 0.9 (1) 0.9 (1) 0.8 (1) 
Phe 1.8 (2) 0.9 (1) 1.0 (1) 1.0 (1) 0.9 (1) 
LYS 3.4 (3) 1.0 (1) 1.1 (1) 1.1 (1) 1.9 (2) 1.0 (1) 
Arg 1.8 (2) 1.1 (1) 1.0 (1) 1.8 (2) 
Sum 32 6 2 5 8 5 6 23 9 
a After hydrolysis for 24 and 72 h 
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Fig.4. Separation of the tryptic peptides of proSSr..32 by 
HPLC using the same chromatographic conditions as 
described in fig.2. Peptides tl-t6 eluted in pure form. 
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Fig.5. The primary structure of peptide proSSr-32 and 
its enzymatic fragments tl-t6, SV8-1 and SV8-2. 
4. DISCUSSION 
The isolation and complete characterization of 
proSSi_32, as shown in fig.6, derived from the N- 
terminal part of porcine prosomatostatin, confirm 
the observations made by Goodman et al. [S] and 
Benoit et al. [20] concerning the cleavage site of the 
signal peptide in the human and rat precursor, 
respectively. In pig, Ala in position 25 of preproSS 
constitutes the N-terminus of proSS. Porcine 
pros%32 is identical to the corresponding se- 
quence in human preproSS, whereas in the rat 
precursor position 19 is Thr for Ala. The post- 
translational processing of preprosomatostatin 
leads to the preferential formation of biologically 
active SS-28 in the gut, but to SS-14 in brain, pan- 
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Fig.6. Schematic synopsis of preprosomatostatin 
(preproSS) and the proposed or isolated peptides derived 
from it; numbers refer to N- or C-terminal amino acid 
residues adjacent to possible cleavage sites. In preproSS, 
residues l-24 represent the signal peptide. 
cress and antrum. Release of SS-281-12, the N- 
terminal part of SS-28, has also been demonstrated 
[28]. Despite the high structural conservation of 
the N-terminal pro-sequence between the rat and 
human precursor, its processing and biological 
function remains unclear. Studies by Benoit et al. 
[19,20] indicate that in addition to the well- 
characterized cleavage sites of preproSS between 
position 24-25, 88-89 and 102-103, generating 
proSS, SS-28 and SS-14, respectively, a fourth pro- 
cessing site at the Leu-Leu bond (position 56-57), 
corresponding to position 32-33 of proSS, may ex- 
ist. Cleavage at this site produces a 5 kDa frag- 
ment, proSS33-76, which contains the SS-28i-i2 se- 
quence as C-terminus (see fig.6). In fact, a peptide 
was isolated from rat brain extracts with N- 
terminal LSEPNQ, corresponding to position 
33-38 of proSS [20]. A similar 5-6 kDa peptide 
containing the SS-14 sequence has been 
demonstrated to be present in a human 
phaeochromocytoma and in normal human in- 
testine [29,30]. 
The existence in porcine gut extracts of 
proSSi-32, being the N-terminal counterpart of the 
5 kDa rat brain peptide (fig.6), supports the 
hypothesis that cleavage of the Leu-Leu bond in 
position 32-33 may represent an important step in 
the processing of proSS. This assumption is in 
good agreement with recent studies of the post- 
translational processing of preproSS in transgenic 
mice [31] suggesting that a 5-6 kDa peptide is 
generated in some tissues, possibly by cleavage 
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within this sequence region. Although being un- 
common, a Leu-Leu cleavage is also invoived in 
the formation of angiotensin I (321. However, it 
cannot be ruled out that cleavage at this site in 
proSS may represent, at least in, part, an artifact 
produced by the extraction method, although dif- 
ferent extraction and chromatography procedures 
were used in the present and previous studies 
[20,29,31]. 
Recently, it has been shown that a peptide de- 
rived from the precursor of gonadotropin-re- 
leasing hormone may represent the sought-after 
prolactin-inhibiting factor [33,34], thus demon- 
strating that pro-sequences of hormones may con- 
tain other biologically active peptides. It remains 
to be seen whether peptide pros&-32 plays a 
regulatory role of its own. 
Meanwhile an antiserum has been raised 
directed against pros&_32 (W.E. Schmidt, un- 
published) which should facilitate studies of the in- 
tracellular processing of the somatostatin precur- 
sor and the physiological function of its N- 
terminal sequence. 
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